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Purpose: To assess the repeatability of apparent diffusion coeffi-
cient (ADC) estimates in extracranial soft-tissue diffusion-
weighted magnetic resonance imaging across a wide range 
of imaging protocols and patient populations.
Materials and 
Methods:
Nine prospective patient studies and one prospective vol-
unteer study, performed between 2006 and 2016 with re-
search ethics committee approval and written informed 
consent from each subject, were included in this single-
institution study. A total of 141 tumors and healthy organs 
were imaged twice (interval between repeated examina-
tions, 45 minutes to 10 days, depending the on study) to 
assess the repeatability of median and mean ADC esti-
mates. The Levene test was used to determine whether 
ADC repeatability differed between studies. The Pearson 
linear correlation coefficient was used to assess correla-
tion between coefficient of variation (CoV) and the year 
the study started, study size, and volumes of tumors and 
healthy organs. The repeatability of ADC estimates from 
small, medium, and large tumors and healthy organs was 
assessed irrespective of study, and the Levene test was 
used to determine whether ADC repeatability differed be-
tween these groups.
Results: CoV aggregated across all studies was 4.1% (range for 
each study, 1.7%–6.5%). No correlation was observed 
between CoV and the year the study started or study 
size. CoV was weakly correlated with volume (r = 20.5, 
P = .1). Repeatability was significantly different between 
small, medium, and large tumors (P , .05), with the low-
est CoV (2.6%) for large tumors. There was a significant 
difference in repeatability between studies—a difference 
that did not persist after the study with the largest tumors 
was excluded.
Conclusion: ADC is a robust imaging metric with excellent repeat-
ability in extracranial soft tissues across a wide range of 
tumor sites, sizes, patient populations, and imaging pro-
tocol variations.
Published under a CC BY 4.0 license.
Online supplemental material is available for this article.
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quantitative imaging biomarkers has 
been proposed by the Radiological So-
ciety of North America Quantitative 
Imaging Biomarkers Alliance (QIBA) 
(12,13). The QIBA framework recom-
mends reporting repeatability by using 
the within-subject standard deviation, 
limits of agreement (LoAs), repeatabil-
ity coefficient (RC), intraclass correla-
tion coefficient (ICC), and within-subject 
coefficient of variance; the QIBA also 
emphasizes the importance of reporting 
measurement conditions. A detailed in-
vestigation of ADC repeatability across 
a wide range of studies using the QIBA 
framework is therefore desirable.
The aim of this study was to assess 
ADC repeatability using the framework 
proposed by the QIBA in extracranial 
soft-tissue DW MR imaging studies to 
investigate whether ADC repeatability 
differs between studies performed by 
using different imaging protocols and 
patient populations over a period of 10 
years at a single institution.
observers, and repetition after a short 
interval (typically 1 hour to 7 days). In 
DW MR imaging–based studies that re-
port ADC estimates, the “measurand” 
is usually the mean or median of ADC 
estimates from voxels in a tumor. On 
the other hand, reproducibility may be 
defined as “closeness of the agreement 
between the results of measurements of 
the same measurand carried out under 
changed conditions of measurement” 
(10)—for example, by using a different 
MR imaging unit. The inter–imaging 
unit reproducibility of ADC estimates 
is particularly important in multicenter 
studies, where it has been shown that 
good-quality DW images with reproduc-
ible ADC estimates across platforms can 
be obtained following careful optimiza-
tion of imaging protocols (11).
Exploratory DW MR imaging stud-
ies in clinical trials often incorporate 
ADC repeatability estimates, usually 
by obtaining two baseline examinations 
with the second examination during the 
same visit (the so-called coffee-break 
repeatability study) or at a second visit 
1 or more days later. The requirement 
for two baseline examinations increases 
the burden on patients, which may re-
duce recruitment or retention rates, and 
requires additional imaging unit time 
and resources, which may be difficult to 
accommodate in busy radiology depart-
ments. It would be advantageous to es-
timate ADC repeatability from previous 
studies, but this would be feasible only 
if repeatability was broadly the same 
across studies, despite variations in im-
aging protocol, tumor type, or patient 
cohort; large differences in repeatability 
would argue strongly for study-specific 
repeatability estimates. The variety of 
repeatability metrics reported in the 
literature hinders comparison between 
studies, and a framework for assess-
ment of the technical performance of 
https://doi.org/10.1148/radiol.2017161965
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Advances in Knowledge
 n Repeated apparent diffusion coef-
ficient (ADC) estimates can be 
obtained from extracranial soft-
tissue diffusion-weighted (DW) 
MR imaging with coefficients of 
variation (CoVs) of between 2% 
and 7%.
 n ADC repeatability does not differ 
markedly (CoV, 2%–7%) 
between DW MR imaging studies 
across a wide range of patient 
cohorts and imaging protocol 
variations.
 n Better ADC repeatability is 
observed in large tumors than in 
smaller tumors.
Implication for Patient Care
 n DW MR imaging can be used to 
estimate ADC with good repeat-
ability in extracranial soft tissues, 
allowing a posttreatment increase 
of 12% or more in ADC to be 
distinguished.
Body diffusion-weighted (DW) mag-netic resonance (MR) imaging is well established as a qualitative 
and quantitative technique in oncology 
(1). The most simple quantitative metric 
derived from DW MR imaging is the ap-
parent diffusion coefficient (ADC), which 
is estimated by fitting a monoexponen-
tial curve to the measured signal at two 
or more diffusion weightings (b values). 
Baseline ADC estimates or posttreatment 
changes in ADC have been shown to be 
indicative of response to chemotherapy 
and/or chemotherapy and radiation ther-
apy in many tumor types, including rectal 
adenocarcinoma (2), hepatic metastases 
of colorectal (3) and gastric (4) cancers, 
cervical cancer (5), breast cancer (6), 
head-and-neck squamous cell carcinoma 
(7), ovarian cancer (8), and non–small 
cell lung cancer (9).
As for all quantitative metrics, the 
repeatability of ADC estimates deter-
mines the ability of the technique to re-
veal treatment-induced changes, thereby 
influencing the number of patients re-
quired for clinical trials and determining 
the size of posttreatment changes that 
can be detected in individual patients. 
Repeatability is usefully defined as “close-
ness of the agreement between the re-
sults of successive measurements of the 
same measurand carried out under the 
same conditions of measurement” (10), 
where, in imaging studies, repeatability 
conditions include use of the same scan-
ner or imaging unit, imaging protocol, 
90 radiology.rsna.org n Radiology: Volume 284: Number 1—July 2017
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within-subject mean squares, K is 
the number of replications (K = 2 for 
all studies in this analysis), Yik is the 
observed value of log(ADCmedian) or 
log(ADCmean) for the ith VOI at the 
kth replication, iY  is the average over 
replications for the ith VOI, and Y  is 
the grand mean of log(ADCmedian) or 
log(ADCmean) over all observations (24).
The 95% confidence inter-
vals (CIs) for sW were estimated as 
, where 
-  is the pth centile of the x2 
distribution with N degrees of freedom 
(24).
95% CIs for ICCs were esti-
mated as 
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In addition to each study being an-
alyzed individually, VOIs were grouped 
into small, medium, and large, regard-
less of study (ie, smallest third, middle 
third, and largest third of VOIs), and 
repeatability was assessed for the three 
groups (47 VOIs per group). Finally, 
VOIs were aggregated from all studies, 
and repeatability was assessed for 141 
VOIs together.
The Levene test for homoscedastic-
ity (Matlab, LeveneAbsolute, vartestn, 
2016a; Mathworks) was used to assess 
whether repeatability differed between 
studies (24). Baseline differences were 
calculated for each VOI for log(ADCmean) 
2
B
2 2
B W
ICC
s
s s
=
+
between studies reflect changes in tech-
nology and personnel (Table 1).
For each tumor or healthy organ, all 
fitted pixels in the ROIs were combined 
to create a VOI. Median and mean 
ADC (ADCmedian and ADCmean) were 
estimated for each VOI. Bland-Altman 
plots of untransformed data showed a 
tendency for differences between pairs 
of baseline measurements to scale with 
their ADC (see Figure E1 [online]), in 
which case it is recommended (13,20) 
that repeatability (and changes due to 
treatment) be quantified by using a pro-
portional (ie, ratio-based) measure so 
that the same measure applies across 
the range of ADCs encountered. This 
can most easily be achieved by using the 
natural logarithm of the data (12,13,20–
22), and this was done for all statistical 
analyses in this study. A paired t test 
was used to assess whether there was a 
significant difference between the first 
and second baseline measurements in 
each study. P , .05 was considered to 
indicate a significant difference.
Repeatability was assessed by using 
the methods recommended by QIBA 
(13). The within-subject standard devi-
ation (sW) of the log-transformed ADC 
estimates was estimated according to 
Equation (1), where di is the difference 
between two baseline estimates of 
log(ADCmedian) or log(ADCmean) for the 
ith VOI, and N is the number of VOIs:
   (1)
The within-subject CoV (23), 95% LoA, 
and RC, which depend only on sW, were 
estimated according to Equations (2), 
(3), and (4), respectively.
 (2)
 (3)
and
  (4)
The ICC was estimated according to 
Equation (5), where sB is the between-
subject standard deviation:
Materials and Methods
Study Population
Nine patient studies and one healthy 
volunteer study were included in this 
analysis. All studies were approved by 
relevant National Research Ethics Com-
mittees. All patients and volunteers 
gave their written consent to partici-
pate in the studies. Only repeatability 
data from double-baseline examina-
tions are reported here; posttreatment 
changes were outside the scope of this 
study but have been reported in the lit-
erature for some studies (14–18).
Tables 1 and 2 describe the sub-
jects and the DW MR imaging proto-
cols for each study (labeled A through 
K); further information is available in 
the references given. All studies were 
performed at 1.5 T by using MAGNE-
TOM Avanto or Aera MR imaging units 
(Siemens) (Table 2). In studies where 
the imaging study or ADC repeatabil-
ity study formed a subset of the total 
cohort (studies C and G), only data in 
patients that contributed to the ADC 
repeatability results are reported. In 
multicenter studies, only data from 
our center are reported (studies D, 
E, and K). In studies including intra-
cranial and extracranial tumors, only 
extracranial data are reported (studies 
A and F). One result (the coefficient of 
variation [CoV] of ADCmedian in study 
K) has been reported previously (11), 
but other results from study K have 
not been reported previously. No other 
results presented here have been re-
ported previously, as publications from 
the original studies included data from 
intracranial tumors (14,15,19) or data 
from other centers (17), which are ex-
cluded from this analysis.
Image and Data Analysis
A total of 141 tumors and healthy organs 
were included in this analysis. All DW 
MR imaging data were fitted by using 
in-house software (Adept, the Institute 
of Cancer Research, London; or Mat-
lab, Mathworks, Natick, Mass). ROIs 
were drawn as described in Table 1. 
Software, methods, and observers were 
fixed within each study; differences 
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and log(ADCmedian), and the Levene test 
was used to assess whether the variance 
of the differences was the same for all 
studies; the Levene test was also used 
to assess whether repeatability differed 
between small, medium, and large VOIs.
The Pearson linear correlation co-
efficient (Matlab, 2016a; Mathworks) 
was used to assess correlation be-
tween CoV and the year the study 
started, the number of VOIs in the 
study, and the median volume of VOIs 
in the study.
Results
The repeatability of ADCmean was sim-
ilar to the repeatability of ADCmedian 
in all studies (Table 3 and Table E1 
[online]); for clarity, only ADCmedian is 
shown in Figures 1–4. Bland-Altman 
plots showed no relationships between 
differences between pairs of base-
line measurements and their means 
(Fig 1). None of the studies showed 
a significant difference between pairs 
of baseline measurements (P . .05, 
paired t test). The repeatability of AD-
Cmedian (Table 3) and ADCmean (Table 
E1 [online]) was good, with CoVs be-
tween 1.7% and 6.3% for ADCmedian 
and between 1.7% and 6.5% for AD-
Cmean for all studies (Fig 2). When we 
aggregated VOIs from all studies, we 
found that CoV was 4.1% for ADCmedian 
and 3.9% for ADCmean, with upper 
and lower 95% LoAs of 12.1% and 
210.8%, respectively, for ADCmedian 
and 11.5% and –10.3% for ADCmean. 
The Levene test showed a significant 
difference between studies (P = .01 for 
ADCmedian and ADCmean) that did not 
persist after the study with the lowest 
CoV (study B, which included some of 
the largest VOIs) was excluded.
There was no correlation between 
the CoV and the year the studies started 
(Fig 3, A; r = 20.4, P = .2 for ADCmedian 
and r = 20.3, P = .3 for ADCmean) nor 
between the CoV and the number of 
VOIs in each study (Fig 3; B, r = 20.3, 
P = .3 for ADCmedian and r = 20.4, P = .2 
for ADCmean). Only weak correlation was 
demonstrated between the CoV and the 
median VOI volume in each study (Fig 
3, C; r = 20.5, P = .1 for ADCmedian and 
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Discussion
The excellent repeatability of ADCmedian 
and ADCmean (CoV, between 1.7% 
and 6.5% in all studies) demonstrates 
that ADC is a robust metric in clinical 
sizes (Levene test; P = .02 for ADCmedian 
and P = .04 for ADCmean), with the low-
est CoV for large VOIs (Fig 4). Although 
19 VOIs in the large group were from 
study B, the majority (28 VOIs) were 
from other studies.
ADCmean), although the CoV was notice-
ably lower in one study with very large 
tumors (study B) compared with other 
studies. Grouping VOIs into small, me-
dium, and large revealed a significant 
difference in ADC repeatability between 
Figure 1
Figure 1: Bland-Altman plot shows percentage change between two baseline estimates of ADC
median
 versus their geometric mean for all VOIs in all studies. Subplots 
A through K3 show Bland-Altman plots for each study (black dots) with VOIs from all other studies shown as gray dots; the x- and y-axis limits are the same as in the 
overall plot. On each plot, solid lines = the mean difference between two baseline examinations for the specified data, dashed lines = 95% LoAs.
Table 3
Repeatability of ADCmedian
Study CoV (%)
95% LoA (%)
RC (log scale) s
W
 (log scale) s
B
 (log scale) ICCUpper Lower
A 4.1 (3.2, 5.6) 11.9 (9.2, 16.6) 210.6 (214.3, 28.5) 0.112 (0.088, 0.154) 0.040 (0.032, 0.055) 0.218 0.967 (0.928, 0.985)
B 1.7 (1.4, 2.4) 4.9 (3.8, 7.0) 24.7 (26.5, 23.7) 0.048 (0.037, 0.068) 0.017 (0.014, 0.024) 0.279 0.996 (0.991, 0.998)
C 3.2 (2.3, 5.2) 9.4 (6.7, 15.5) 28.6 (213.4, 26.3) 0.090 (0.065, 0.144) 0.032 (0.023, 0.052) 0.256 0.984 (0.951, 0.995)
D 6.3 (4.5, 10.7) 19.0 (13.1, 34.4) 216.0 (225.6, 211.6) 0.174 (0.123, 0.296) 0.063 (0.045, 0.107) 0.251 0.941 (0.806, 0.984)
E 6.2 (4.2, 11.3) 18.6 (12.5, 36.6) 215.7 (226.8, 211.1) 0.171 (0.118, 0.312) 0.062 (0.042, 0.113) 0.147 0.851 (0.504, 0.964)
F 3.0 (2.1, 5.8) 8.8 (5.9, 17.5) 28.1 (214.9, 25.5) 0.084 (0.057, 0.162) 0.030 (0.021, 0.058) 0.217 0.981 (0.915, 0.996)
G 3.9 (2.6, 7.5) 11.4 (7.6, 23.1) 210.3 (218.8, 27.1) 0.108 (0.073, 0.208) 0.039 (0.026, 0.075) 0.140 0.928 (0.709, 0.985)
H 4.0 (2.7, 8.2) 11.8 (7.7, 25.6) 210.6 (220.4, 27.1) 0.112 (0.074, 0.228) 0.040 (0.027, 0.082) 0.150 0.932 (0.696, 0.988)
J 5.2 (3.4, 11.5) 15.5 (9.7, 37.4) 213.4 (227.2, 28.9) 0.144 (0.093, 0.317) 0.052 (0.034, 0.115) 0.302 0.971 (0.839, 0.996)
K1 2.6* (1.8, 4.6) 7.5 (5.2, 13.6) 27.0 (212.0, 24.9) 0.073 (0.051, 0.127) 0.026 (0.018, 0.046) 0.023 0.427 (20.205, 0.816)
K2 2.9* (2.0, 5.1) 8.4 (5.8, 15.2) 27.8 (213.2, 25.5) 0.081 (0.056, 0.142) 0.029 (0.020, 0.051) 0.042 0.677 (0.158. 0.907)
K3 6.1* (4.3, 10.7) 18.4 (12.5, 34.5) 215.6 (225.7, 211.1) 0.169 (0.118, 0.297) 0.061 (0.043, 0.107) 0.023 0.126 (20.491, 0.673)
All† 4.1 (3.7, 4.7) 12.1 (10.8, 13.8) 210.8 (212.2, 29.7) 0.115 (0.103, 0.130) 0.041 (0.037, 0.047) 0.309 0.982 (0.976, 0.987)
Note.—Data in parentheses are lower and upper 95% CIs. sB = between-subject standard deviation, sW = within-subject standard deviation. Estimates of ADCmedian for two baseline examinations for 
all tumors/organs are tabulated in Table E2 (online).
* CoVs from K1, K2, and K3 reproduced from Winfield et al (11) for completeness.
† Results are shown for each study and for all VOIs (“All”) analyzed together.
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can be assessed by using a t test or 
similar); knowledge of measurement 
repeatability is also essential in power 
calculations to estimate the sample size 
necessary to detect a treatment effect 
in prospective cohort studies. Con-
sidering changes in ADC after treat-
ment, an increase of 12% or more in 
ADCmedian or ADCmean would be outside 
the 95% LoA for all VOIs analyzed 
together; even considering the stud-
ies with the poorest repeatability (ie, 
“worst-case” studies), an increase of 
20% would have been outside the 95% 
LoA in all studies. A tumor exhibiting 
such a change in ADC after treatment 
would therefore be assessed as exhibit-
ing a posttreatment effect outside the 
expected variation of repeated mea-
surements, with 95% confidence, when 
measured with the same imaging unit 
by using the same imaging protocol, 
operator, and reader (ie, in repeatabil-
ity conditions). This can be compared 
with posttreatment changes reported 
elsewhere: 23% and 24% increases in 
ADCmean in responding patients with 
hepatic metastases from colorectal (3) 
and gastric (4) cancers, respectively; 
and increases of 20% (ADCmean) and 
22% (ADCmedian) in responding patients 
with ovarian cancer treated with plati-
num-based chemotherapy (8). In stud-
ies reporting ADC changes in individual 
patients, as opposed to cohort changes, 
posttreatment increases in ADCmean of 
up to 100% were reported in patients 
with cervical cancer after chemoradio-
therapy (5), and increases in ADCmean 
of up to 50% were reported in patients 
with non–small cell lung cancer (9). 
Hence, the excellent repeatability dem-
onstrated in the present analysis shows 
that ADC is sensitive to changes that 
are observed in clinical studies.
The significant difference between 
small, medium, and large VOIs shows 
that volume is an important factor in 
ADC repeatability. The weak correla-
tion between the CoV and the median 
VOI volume in each study may reflect 
the range of tumor sizes within each 
study. The low CoV of 1.7% in study 
B may relate to the large tumors in 
that study. For future studies, the as-
sumption of a CoV of 6.5% would be a 
for their respective metrics. Addition-
ally, most studies do not report CIs, 
which further hinders comparison.
The CoV and LoA, expressed as 
percentages, may be more intuitive for 
investigators to understand, compared 
with sW or RC expressed on a log scale. 
Although the ICC is listed in the QIBA 
framework for reporting repeatability, 
ICC may not be an appropriate metric 
for comparison between studies because 
results are scaled to the intersubject var-
iability of the study cohort by sB; a low 
ICC may therefore reflect a homoge-
neous cohort rather than poor repeat-
ability (13). This is exemplified in study 
K, where ICCs were low (0.126–0.677 
in studies K1, K2, and K3) despite the 
CoVs being comparable with those in 
other studies. Values of sB were an or-
der of magnitude lower than in studies 
A through J, reflecting the narrow range 
of ADC estimates in healthy organs in 
the tightly controlled volunteer cohort. 
These results strongly suggest that the 
ICC should not be used to compare ADC 
repeatability between studies.
Knowledge of ADC repeatability is 
essential for assessment of posttreat-
ment changes in an individual patient 
(as opposed to cohort changes, which 
practice in oncology. The results re-
ported in this analysis are comparable 
with results from similar test-retest re-
peatability studies, although compari-
son with the literature is hindered by 
the variety of metrics that have been 
reported. From the published litera-
ture, a study of malignant hepatic tu-
mors (26) reported ICCs in the range 
of 0.898 to 0.933 and LoAs in the range 
of 18.8%–24.0% for ADCmean. A study 
in head-and-neck squamous cell carci-
noma (27) reported an RC of 15% for 
ADCmean. A study of hepatocellular car-
cinoma (28) reported a CoV of 8.3% 
and a lower and upper LoA of 241.1% 
and 18.6%, respectively, for ADCmean. 
A study in abdominal organs in healthy 
volunteers (29) reported RCs between 
6.4% and 9.6% for ADCmean. A study 
of normal thyroid glands in healthy vol-
unteers that used reduced-field-of-view 
DW MR imaging (30) and that also fol-
lowed the QIBA framework reported an 
sw
2 of 0.0147 3 1023mm2 sec21, an RC 
of 0.3355 3 1023mm2 sec21, an ICC of 
0.9273, and a CoV of 9.88%. Compar-
ison between published studies is not 
straightforward because they report 
different repeatability metrics, but each 
result is similar to the present analysis 
Figure 2
Figure 2: Graph shows CoVs of ADC
median
 for each study (A through K3); all VOIs analyzed 
together (All); and all tumor VOIs analyzed together (All tumors). Whiskers = 95% CIs for CoV 
estimates.
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study commenced may suggest that ADC 
repeatability has not changed markedly 
over 10 years despite advances in MR 
imaging unit technology and imaging 
protocol methods during that time. 
This suggests that ADC repeatability 
assessments from older studies may in-
form future studies, although this may 
not apply across substantial changes in 
hardware and/or methods, such as a 
change in field strength. Although this 
analysis considered only ADC repeat-
ability, imaging protocol variations may 
also affect overall image quality, qualita-
tive interpretation, and absolute values 
of ADC estimates, but these effects 
are outside the scope of this analysis. 
Reasons for variations in imaging pro-
tocols include changes in hardware 
and software capabilities; advances in 
knowledge; requirements for imaging 
particular patient cohorts, such as the 
size of the field of view or the orienta-
tion of the imaging plane; requirements 
of study sponsors; and requirements to 
match protocols in multicenter studies.
The apparent absence of a relation-
ship between the CoV and the number 
of VOIs in the study (over the range 
of six to 26 VOIs) may suggest that an 
informative estimate of repeatability 
may be obtained from as few as six pa-
tients, indicating that double-baseline 
examinations in relatively small subsets 
of patients may be used to efficiently 
Furthermore, larger tumors may be less 
affected by motion or partial-volume 
effects, which may lead to better ADC 
repeatability. ADC repeatability in pe-
diatric patients (study F) was not worse 
than that in other studies, despite the 
additional challenges associated with 
patient compliance in this group.
The apparent absence of a relation-
ship between the CoV and the year the 
conservative choice. It is worthwhile to 
note that the VOIs did not always en-
compass the whole tumor: ROIs were 
drawn around the whole area of the tu-
mor or healthy organ on at least three 
sections in all studies, but studies A, B, 
and E included considerably more sec-
tions. Larger VOIs may provide more 
robust estimates of ADCmedian and AD-
Cmean because of larger sample sizes. 
Figure 4
Figure 4: Bar graph shows CoVs of ADC
median
 for 
small, medium, and large VOIs, all VOIs together, 
and all VOIs excluding study B. Error bars = 95% 
CIs of CoV estimates.
Figure 3
Figure 3: Plots of CoVs of ADC
median
 versus, A, the year the study started, B, the number of VOIs (subjects 
or lesions) in the study, and, C, the natural logarithm of the median volume of the VOIs in the study. Error  
bars = 95% CIs of CoV estimates. In A and B, studies with identical start dates or numbers of VOIs have 
been offset for clarity.
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estimate repeatability for larger stud-
ies. Repeatability studies may thus be 
easily conducted if a center wishes to 
assess its DW MR imaging protocols. 
Inclusion of larger numbers of subjects, 
however, allows narrower CIs to be 
placed on estimated quantities and is 
advocated in clinical trials.
Repeatability estimates for ADCmedian 
and ADCmean do not apply to all sum-
mary statistics; for example, other ADC 
histogram centiles may exhibit poorer 
repeatability (31). Alternative acquisi-
tion techniques (eg, motion compensa-
tion) would also require new repeatabil-
ity studies. Furthermore, it is common 
practice to use data from previous im-
aging studies to develop novel analysis 
methods, which require assessment of 
the repeatability of resulting metrics to 
evaluate their potential value in clinical 
practice. Double-baseline studies there-
fore provide an invaluable resource 
for future developments of analysis 
methods.
There were limitations to our 
analysis. First, all studies were per-
formed at a single expert center, and 
senior members of staff with extensive 
experience of extracranial DW MR im-
aging were involved in the development 
of imaging protocols for all studies. Sec-
ond, all but one of the studies were per-
formed with the same MR imaging unit, 
with the remaining study performed on 
a unit from the same manufacturer; 
the generality of our conclusions for 
test-retest measurements across MR 
imaging unit from other manufacturers 
remains to be tested. Third, only one 
study in healthy volunteers was in-
cluded. Fourth, many of the studies 
were substudies that formed part of a 
larger clinical trial, and there may have 
been selection bias because of inclusion 
and exclusion criteria for these trials 
(eg, including patients with lesions . 
2 cm or excluding patients who had 
difficulty lying still). Generalization to 
routine clinical practice remains to be 
tested, but the repeatability of ADC 
estimates in less-controlled situations 
might be expected to be worse than the 
repeatability reported here.
In conclusion, ADC is a robust imag-
ing metric that demonstrates excellent 
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